Epiva Therapeutics

Cambridge, United States Founded: 2015 • Age: 11 yrs Acquired By Evelo Biosciences
Microbiome-based therapeutics are developed for autoimmune diseases.

About Epiva Therapeutics

Epiva Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2015, and was acquired by Evelo Biosciences in July 2016. Microbiome-based therapeutics are developed for autoimmune diseases. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its competitors include Biogen, Insitro and BridgeBio; 3 of its 3 listed competitors have raised funding.

Company details

Epiva Therapeutics was founded in 2015 in Cambridge, United States, as a microbiome-focused company originating from Flagship VentureLabs. Operations center on the development of therapeutics targeting autoimmune diseases linked to microbiome dysbiosis. The sector involves biotechnology applications in gut microbiome modulation to address immune dysregulation. Research and therapeutic innovation are conducted in the United States, with a emphasis on clinical translation for dysbiosis-associated conditions.

Key Metrics

Investors in Epiva Therapeutics

Epiva Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Evelo Biosciences.

All
InvestorDescriptionFounded YearDomainLocation
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
2015evelobio.comCambridge, United States
Premium access

Investor details for Epiva Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Epiva Therapeutics

2 dated milestones of Epiva Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.

  1. Founded Epiva Therapeutics is founded.
  2. Exit Acquired by Evelo Biosciences.

Competitors of Epiva Therapeutics

Epiva Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Insitro and BridgeBio.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
biogen.com1978Cambridge, United States$80M1
Therapies for neurodegenerative and immunology disorders are developed.
insitro.com2018San Francisco, United States$643.21M257
An AI-enabled platform is developed for infectious disease treatment.
bridgebio.com2015Palo Alto, United States$434.2M
Therapeutics for genetic diseases are developed through targeted interventions.
Premium access

Detailed competitors of Epiva Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Epiva Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Epiva Therapeutics

Epiva Therapeutics was founded in 2015.

Epiva Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Epiva Therapeutics was founded in 2015 in Cambridge, United States, as a microbiome-focused company originating from Flagship VentureLabs. Operations center on the development of therapeutics targeting autoimmune diseases linked to microbiome dysbiosis. The sector involves biotechnology applications in gut microbiome modulation to address immune dysregulation. Research and therapeutic innovation are conducted in the United States, with a emphasis on clinical translation for dysbiosis-associated conditions.

Epiva Therapeutics's top competitors include BridgeBio, Insitro and Biogen.

Epiva Therapeutics has 1 investor. Key investors include Evelo Biosciences.

Yes. Epiva Therapeutics was acquired by Evelo Biosciences in July 2016.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available